Leptomeningeal relapse in primary cutaneous <scp>DLBCL</scp>: Implications for a prophylactic <scp>CNS</scp> therapy

Sundriyal, Deepak; Arya, Lima; Srivastava, Ruchi; Walia, Meenu; Sehrawat, Amit

doi:10.1002/cnr2.1295

Cited by 2 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two hundred seventy-two articles reported on 553 patients with otologic manifestations of hematologic malignancies, of which 255 (93.8%) were case reports and of OECBM level V evidence and 17 (6.2%) were case series and of OECBM level IV evidence (Supplement 3, http://links.lww.com/MAO/B834; Supplement 4, http://links.lww.com/MAO/B835) (4,5,7–10,13,14,19–282). While the largest proportion of articles originated in the United States (n = 83, 30.5%), the literature spanned countries across all continents.…”

Section: Resultsmentioning

confidence: 99%

A Scoping Review of Otologic Manifestations of Hematologic Malignancies

Raymond,

Ottinger,

Rowley

et al. 2024

Otol Neurotol

View full text Add to dashboard Cite

Objective To examine the otologic and neurotologic symptoms, physical examination findings, and imaging features secondary to hematologic malignancies. Methods Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, databases, including PubMed, Scopus, and CINAHL, were searched for articles including patients with otologic manifestations of leukemia, lymphoma and multiple myeloma. Data collected included patient and study demographics, specific hematologic malignancy, timing and classification of otologic symptoms, physical examination findings, imaging features and methods of diagnosis. Pooled descriptive analysis was performed. Results Two hundred seventy-two articles, of which 255 (93.8%) were case reports and 17 (6.2%) were case series, reporting on 553 patients were identified. Otologic manifestations were reported on 307 patients with leukemia, 204 patients with lymphoma and 42 patients with multiple myeloma. Hearing loss and unilateral facial palsy were the most common presenting symptoms for 111 reported subjects with leukemia (n = 46, 41.4%; n = 43, 38.7%) and 90 with lymphoma (n = 38, 42.2%; n = 39, 43.3%). Hearing loss and otalgia were the most common presenting symptoms for 21 subjects with multiple myeloma (n = 10, 47.6%; n = 6, 28.6%). Hearing loss and unilateral facial palsy were the most common otologic symptoms indicative of relapse in subjects with leukemia (n = 14, 43.8%) and lymphoma (n = 5, 50%). Conclusion Hearing loss, facial palsy, and otalgia might be the first indication of a new diagnosis or relapse of leukemia, lymphoma, or multiple myeloma. Clinicians should have a heightened level of suspicion of malignant etiologies of otologic symptoms in patients with current or medical histories of these malignancies.

show abstract

Section: Resultsmentioning

confidence: 99%

A Scoping Review of Otologic Manifestations of Hematologic Malignancies

Raymond,

Ottinger,

Rowley

et al. 2024

Otol Neurotol

View full text Add to dashboard Cite

show abstract

“… 7 , 8 While there is currently no evidence-based standard of care, most cases of PCDLBCL, LT are treated as systemic DLBCL, with R-CHOP chemoimmunotherapy, often with central nervous system prophylaxis, due to the high risk of central nervous system dissemination. 9 The addition of radiation therapy to chemoimmunotherapy was found to be important in a recent case series. 10 Despite historical data showing that the outcomes of patients with PCDLBCL,LT have improved since the introduction of modern chemoimmunotherapy, outcomes remain relatively poor.…”

mentioning

confidence: 99%